🇺🇸
SUZHOU, China and MÖLNDAL, Sweden, Oct. 8, 2026 /PRNewswire/ — Suzhou Ribo Life Science (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as “Ribo”) announced the successful submission of a Phase Ⅰ Clinical Trial Application (CTA) in EU for RBD3133, a…
Source: prnewswire
Country: United States